Evolva to co-develop next-generation materials with US Navy
Evolva announced that it has completed a Limited Purpose Cooperative Research and Development Agreement (CRADA) to support the joint development of novel advanced materials with the US Navy. The focus of the efforts supported by this CRADA relate to the development, validation and potential commercialisation of new lightweight, fire-resistant composite materials to save lives and reduce harm from fire.
Applications of these advanced materials include aircraft, waterborne craft, fabrics, armoured vehicles, and construction materials. These next-generation composite materials are based on a molecule that can be manufactured on an industrial scale using advanced biotechnology and fermentation, and then polymerised and shaped/moulded using standard fabrication techniques.
If successful, this project would create for the US Navy novel composite materials that are fire resistant, stronger and lighter than aluminium, and capable of withstanding high temperatures. These materials would also be more sustainably sourced, less expensive, and offer a number of other advantages over existing composites.
“This agreement highlights and validates the versatility of our product innovation platform and depth of our plant science expertise,” said Evolva CEO Neil Goldsmith. “This CRADA also illustrates just how far and wide Evolva is making inroads across multiple industries with its building-with-biology platform.”
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Haemophilia_A
Sulfate-reducing_bacteria
International_Centre_for_Diarrhoeal_Disease_Research,_Bangladesh
Isotretinoin
Congenital_adrenal_hyperplasia_due_to_3_beta-hydroxysteroid_dehydrogenase_deficiency
Thalassemia
Sugarman_syndrome
Expansion of Genedata's Collaboration with Serono into High Content Screening
Santhera Presents New Data on MC-4R Antagonist Program for Treatment of Cancer Cachexia

IKA G-L | Midi centrifuges | IKA Werke
